Search results
Results from the WOW.Com Content Network
The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. [3] From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. [1]
ChemDraw is a molecule editor first developed in 1985 by Selena "Sally" Evans, her husband David A. Evans, and Stewart Rubenstein [1] [2] (later by the cheminformatics company CambridgeSoft). The company was sold to PerkinElmer in 2011. [ 3 ]
[1] [2] The branches of science known informally as omics are various disciplines in biology whose names end in the suffix -omics, such as genomics, proteomics, metabolomics, metagenomics, phenomics and transcriptomics. The related suffix -ome is used to address the objects of study of such fields, such as the genome, proteome or metabolome ...
On Monday, Revvity Inc. (NYSE:RVTY) reported second-quarter sales of $691.69 million, down from $709.07 million, beating the consensus of $690.36 million. The life sciences and diagnostics company ...
Gedela Srinubabu is an Indian businessman, scientist and politician.He is the chief executive officer of Pulsus Group and founder of its parent company the OMICS Publishing Group, a scientific journal publishing company that publishes science findings online for free for readers.
Multiomics, multi-omics, integrative omics, "panomics" or "pan-omics" is a biological analysis approach in which the data sets are multiple "omes", such as the genome, proteome, transcriptome, epigenome, metabolome, and microbiome (i.e., a meta-genome and/or meta-transcriptome, depending upon how it is sequenced); [1] [2] [3] in other words ...
OMICS Publishing Group was founded in 2007 by Gedela Srinubabu, [18] who remains the company's director. [19] [20] He founded OMICS because of his difficulty in accessing high-cost journal contents as a PhD student.
[3] [4] [5] WIN 55,212-2 is a potent cannabinoid receptor agonist [6] that has been found to be a potent analgesic [7] in a rat model of neuropathic pain. [8] It activates p42 and p44 MAP kinase via receptor-mediated signaling. [9] At 5 μM WIN 55,212-2 inhibits ATP production in sperm in a CB 1 receptor-dependent fashion. [10]